stoxline Quote Chart Rank Option Currency Glossary
Autolus Therapeutics plc (AUTL)
4.52  -0.28 (-5.83%)    04-19 16:00
Open: 4.75
High: 4.84
Volume: 1,402,269
Pre. Close: 4.8
Low: 4.485
Market Cap: 787(M)
Technical analysis
2024-04-19 5:07:53 PM
Short term     
Mid term     
Targets 6-month :  6.78 1-year :  7.73
Resists First :  5.8 Second :  6.62
Pivot price 5.2
Supports First :  4.48 Second :  3.73
MAs MA(5) :  4.78 MA(20) :  5.47
MA(100) :  5.77 MA(250) :  3.99
MACD MACD :  -0.4 Signal :  -0.3
%K %D K(14,3) :  1.1 D(3) :  1.2
RSI RSI(14): 27.9
52-week High :  7.44 Low :  1.61
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AUTL ] has closed above bottom band by 0.3%. Bollinger Bands are 19.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.87 - 4.92 4.92 - 4.95
Low: 4.39 - 4.45 4.45 - 4.48
Close: 4.45 - 4.55 4.55 - 4.61
Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Headline News

Sat, 20 Apr 2024
Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 3.7% - Defense World

Fri, 19 Apr 2024
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.2% - MarketBeat

Fri, 19 Apr 2024
RSI Alert: Autolus Therapeutics (AUTL) Now Oversold - Nasdaq

Fri, 19 Apr 2024
Recent 9.9% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still ... - Simply Wall St

Fri, 19 Apr 2024
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.86 - Defense World

Sun, 17 Mar 2024
Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 266 (M)
Held by Insiders 9.118e+007 (%)
Held by Institutions 18 (%)
Shares Short 2,770 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.6896e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -10 %
Return on Assets (ttm) 337.3 %
Return on Equity (ttm) -25.4 %
Qtrly Rev. Growth 1.7e+006 %
Gross Profit (p.s.) -51.82
Sales Per Share -52.65
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -146 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.09
Price to Cash Flow 13.63
Stock Dividends
Dividend 0
Forward Dividend 4.17e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android